Media Centre

May 6, 2011
Piramal Life Sciences Limited and Piramal Healthcare Limited-Demerger of the NCE Research Unit of Piramal Life Sciences Limited into Piramal Healthcare Limited
Piramal Life Sciences Limited (NSE: PIRLIFE, BSE: 532979) and Piramal Healthcare Limited (NSE: PIRHEALTH, BSE: 500302) today announced that the Boards of both the companies considered and approved the scheme of Arrangement between PLSL and PHL (“Demerger Scheme”).

March 9, 2010
Piramal Life Sciences Introduces Tinefcon, its Newly Developed Natural Remedy for Psoriasis at American Academy of Dermatology Convention in Miami, USA.
Piramal Life Sciences Limited, member of the Piramal Group of companies, today will make a presentation during the 68th Scientific Session of American Academy of Dermatology being convened at Miami Beach, Florida, USA, March 5 – 9, 2010.

May 30, 2008
Piramal Life Sciences Limited now a listed company
Piramal Life Sciences Limited ("PLSL"), a research and development company recently demerged from Piramal Healthcare Limited ("PHL"), previously known as Nicholas Piramal India Limited ("NPIL"), was today listed

Tinefcon®

A revolutionary treatment for Psoriasis from Piramal Life Sciences
PLSL has discovered and developed a new medication (Tinefcon®) for psoriasis that works through a mechanism that is different from conventional drugs (steroids, immunosuppressants) yet is effective & safe. The efficacy & safety of Tinefcon® has been evaluated in three clinical trials, one of which was discussed at the recent conference of the American Association of Dermatology (AAD).